Document is current

Article History

Received: 27 January 2022

Accepted: 22 July 2022

First Online: 5 September 2022

Declarations

:

: The study is being conducted in compliance with the Declaration of Helsinki and International Council for Harmonization Guidelines for Good Clinical Practice. The protocol will be approved by each site’s governing ethical body. Each study patient is required to have provided written informed consent prior to the conduct on any study-related procedures.

: Not applicable.

: Dafna D. Gladman received grant support from AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB and consulting fees from AbbVie, Amgen, BMS, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. Philip J. Mease has received research support from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; consultant fees from AbbVie, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB. Paul Bird received speaker honoraria from AbbVie, Eli Lilly, Gilead, Janssen, MSD, Pfizer, and UCB; served as advisor for Eli Lilly, Gilead, Janssen, Novartis, and Pfizer. Enrique R. Soriano has served as advisor for AbbVie, Janssen, Novartis, and Roche; has received grant/research support from AbbVie, Janssen, Novartis, Pfizer, Roche, and UCB; has served as speaker/received honoraria from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB. Soumya D. Chakravarty, Sean T. Quinn, Cinty Gong, and Evan Leibowitz are employees of Janssen Scientific Affairs, LLC, and own stock or stock options in Johnson & Johnson, of which Janssen Scientific Affairs is a wholly owned subsidiary. May Shawi is an employee of Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson and owns stock or stock options in Johnson & Johnson. Stephen Xu is an employee of Janssen Research & Development and owns stock or stock options in Johnson & Johnson, of which Janssen Scientific Affairs is a wholly owned subsidiary. Denis Poddubnyy has received consulting fees from AbbVie, Biocad, Bristol-Myers Squibb, Eli Lilly, Gilead, GlaxoSmithKline, MSD, Novartis, Pfizer, Roche, and UCB and grants from AbbVie, Eli Lilly, MSD, Novartis, and Pfizer. Lai-Shan Tam has received grant/research support from Amgen, Boehringer Ingelheim, Janssen, GlaxoSmithKline, Novartis, and Pfizer, and has acted as a consultant for AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, Pfizer, and Sanofi. Philip S Helliwell has received speaker payment from AbbVie, Janssen, and Novartis; consulting fees from Eli Lilly, Galapagos, Janssen, and Pfizer. Arthur Kavanaugh has received consulting fees from AbbVie, Amgen, BMS, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer and UCB. Atul Deodhar received consulting fees for participation in Advisory Boards from AbbVie, Amgen, Aurinia, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, MoonLake, Novartis, Pfizer, and UCB; Research Grant funding from AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, and UCB; and Speaker fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Mikkel Østergaard received research grants from AbbVie, Bristol Myers Squibb, Celgene, and Novartis, and speaker and/or consultancy fees from AbbVie, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB. Xenofon Baraliakos has received consulting fees, grant/research support/speaker support from AbbVie, Biocad, Chugai, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, and UCB.